Registry for prostate cancer treatment and outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to document the treatment course and disease progression in patients with recurrent and metastatic prostate cancer. It includes various cohorts such as those with biochemical recurrence after local treatment, non-metastatic castration-resistant prostate cancer, and metastatic hormone-sensitive and castration-resistant prostate cancer. Patients will be followed over time with routine data collection on their treatment and quality of life, allowing for a comprehensive understanding of real-world outcomes. The study does not specify any particular treatment, as all therapies will be determined by the treating physicians.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult prostate cancer patients (age ≥18 years).
* Diagnosis at time of study inclusion Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof) Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line)
* Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, … line).
* For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient.
* Patients, who are able and willing to sign the informed consent form

Exclusion Criteria:

• Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician

Where it's running

• Universitätsklinikum Freiburg
  Freiburg im Breisgau, Baden-Wurttemberg, Germany Recruiting
• National Center for Tumor Dieseases (NCT) Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany Recruiting
• University Hospital Mannheim
  Mannheim, Baden-Wurttemberg, Germany Recruiting
• Medical Office for Urology Nürtingen
  Nürtingen, Baden-Wurttemberg, Germany Recruiting
• Studienpraxis Urologie
  Nürtingen, Baden-Wurttemberg, Germany Recruiting
• University Hospital Tübingen
  Tübingen, Baden-Wurttemberg, Germany Recruiting

+3 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Andrea Rößler, PhD
• Email: andrea.roessler@urotrials.de
• Phone: 00491736872306

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• JANX014 for metastatic castration-resistant prostate cancer

  This trial will test whether JANX014 is safe, how your body handles it, and whether it shows signs of benefit in adults with metastatic castration-resistant prostate cancer who have already had anti-androgen therapy and typically a taxane.

  Recruiting at 6 sites Phase 1 Janux Therapeutics · La Jolla, California and 5 other locations · NCT07545811

• Shorter Salvage Radiotherapy after Prostate Surgery for Recurrent Prostate Cancer

  This study tests whether a shorter, 4-week salvage radiotherapy schedule is as safe and effective as the standard 5-week schedule for men with prostate cancer that has come back after surgery.

  Recruiting CHU de Quebec-Universite Laval · Gatineau, Quebec and 3 other locations · NCT07483658

• Actinium (225Ac) PSMA therapy for castration‑resistant prostate cancer after Lutetium

  This trial will test whether an injectable Actinium-225 PSMA treatment can control advanced prostate cancer in men whose disease progressed after Lutetium‑PSMA therapy.

  Recruiting Phase 1/2 University College, London · London · NCT07414940

• A-CAR032 CAR-T therapy for metastatic castration-resistant prostate cancer

  This early-phase treatment will try A-CAR032, a CAR-T cell therapy, in adults with metastatic castration‑resistant prostate cancer who progressed after ARPI and are not eligible for standard treatment.

  Recruiting at 2 sites Phase 1 Shanghai AbelZeta Ltd. · Beijing, Beijing Municipality and 3 other locations · NCT07344311

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.